Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes

Table 3 Comparison of characteristics and 28-day survival rate according to AKI stage

	AKI stage 1	AKI stage 2	AKI stage 3	P value
Number of patients [n (%)]	212	416	1512
Sex (% female)	39.2	31.3	33.1	0.129
Age (years)	70.0 ± 14.3	69.4 ± 15.3	69.1 ± 14.7	0.632
APACHE II score	22.2 ± 9.2	23.0 ± 8.8	24.4 ± 9.2	0.0001
SOFA score	8.7 ± 3.9	9.9 ± 4.2	10.7 ± 4.3	< 0.0001
Comorbid sepsis [n (%)]	51.4	43.0	40.0	0.005
Renal replacement therapy [n (%)]	192 (90.5)	388 (93.2)	1459 (96.6)	< 0.0001
CRRT [n (%)]	136 (70.8)	318 (82.0)	1134 (77.7)
IRRT [n (%)]	49 (25.5)	42 (10.8)	226 (15.5)
Both CRRT and IRRT [n (%)]	7 (3.7)	28 (7.2)	99 (6.8)
PMX-DHP [n (%)]	28 (13.2)	41 (9.9)	99 (6.5)	0.001
Survival rate (%)	68.9	63.5	58.8	0.001

AKI acute kidney injury, APACHE Acute Physiology and Chronic Health Evaluation, CRRT continuous renal replacement therapy, IRRT intermittent renal replacement therapy, PMX-DHP direct hemoperfusion with polymyxin B-immobilized fiber column

ISSN: 2059-1381